WO2022207906A1 - Diagnostic methods of prostate cancer - Google Patents

Diagnostic methods of prostate cancer Download PDF

Info

Publication number
WO2022207906A1
WO2022207906A1 PCT/EP2022/058754 EP2022058754W WO2022207906A1 WO 2022207906 A1 WO2022207906 A1 WO 2022207906A1 EP 2022058754 W EP2022058754 W EP 2022058754W WO 2022207906 A1 WO2022207906 A1 WO 2022207906A1
Authority
WO
WIPO (PCT)
Prior art keywords
radioligand
psma
imaging agent
pet
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/058754
Other languages
English (en)
French (fr)
Inventor
Ana CATAFAU
Elisabet PARERA PIELLA
Beilei HE
Euloge KPAMEGAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Advanced Accelerator Applications SA
Original Assignee
Novartis AG
Advanced Accelerator Applications SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Advanced Accelerator Applications SA filed Critical Novartis AG
Priority to JP2023560269A priority Critical patent/JP2024514293A/ja
Priority to KR1020237032903A priority patent/KR20230165761A/ko
Priority to CN202280026305.2A priority patent/CN117120100A/zh
Priority to IL307381A priority patent/IL307381A/en
Priority to EP22720606.7A priority patent/EP4313175A1/en
Priority to CA3215723A priority patent/CA3215723A1/en
Priority to US18/552,760 priority patent/US20240181092A1/en
Publication of WO2022207906A1 publication Critical patent/WO2022207906A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Definitions

  • the present disclosure relates to the field of diagnostic methods, and more particularly prostate cancer imaging.
  • Prostate-specific membrane antigen is a transmembrane protein, also known as folate hydrolase or glutamate carboxypeptidase II. From all the known PSMA-overexpressing tumors, prostate cancer is the one in which the role of PSMA has been most extensively studied. Prostate cancer remains the cancer with the second highest mortality in the United States (US), and the third leading cause of cancer-related death in Europe in men (Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin; 67(l):7-30, Malvezzi M, Carioli G, Bertuccio P, et al (2019) European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol; 30(5):781-7).
  • Subsequent treatment is multifaceted and may involve observation, surgery (prostatectomy), radiation therapy (external beam or brachytherapy), hormonal therapy, chemotherapy.
  • the differential expression of PSMA from tumor to non-tumor tissue has resulted in numerous targeted strategies involving both disease localization using PSMA-PET imaging as well as therapeutic intervention. Correct identification of disease location and extent determines treatment decisions for patients with prostate cancer. Identification of distant metastatic disease at the early stages of prostate cancer is thus important in planning prostate cancer management.
  • the usual diagnostic tools for prostate cancer include PSA testing, digital rectal palpation, transrectal ultrasound, prostate biopsy, and histopathologic examination (Schwarzenbock S, Souvatzoglou M, Krause BJ (2012). Theranostics; 2(3):318-30; Smith RA, Andrews K, Brooks D, et al (2016) Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin; 66(2):95- 114; Prasad V, Steffen IG, Diederichs G, et al (2016). Mol Imaging Biol; 18:428-36).
  • PET/CT are used for staging primary prostate cancers and restaging biochemical recurrences (Schwarzenbock S, Souvatzoglou M, Krause BJ (2012) Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer. Theranostics; 2(3):318-30).
  • CT and MRI are the standard of care imaging procedures for measuring tumors at baseline and lesions selected for response assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer; 45:228- 47).
  • RECIST Solid Tumors
  • PET imaging is an enticing choice as it offers the potential to both stage patients and provide insight into tumor biology.
  • 68 Ga-labeled ligands of the PSMA were associated with unprecedented accuracy and effect on treatment in several meta-analyses of retrospective studies (Perera M, Papa N, Christidis D, et al (2016). Eur Urol; 70:926-37; Han S, Woo S, Kim YJ, et al (2016). Eur Urol; 74:179-90, Von Eyben EE, Picchio M, von Eyben R, et al (2016).
  • [ 18 F]CTT1057 is a promising novel PSMA-targeting I8 F-labeled PET imaging agent (WO2014143736). Unlike most other PSMA agents labelled with either 68 Ga or 18 F (e.g. [ 68 Ga]Ga-PSMA-ll, [ 18 F]PSMA1007, [ 18 F]DCFPyL) which share a urea backbone, [ 18 F]CTT1057 is based on a phosphoramidate scaffold that irreversibly binds to PSMA with high nanomolar affinity, which may account for a higher and prolonged tumor uptake (Behr SC, Aggarwal R, VanBrocklin HF, et al (2019) Phase I Study of CTT1057, an 1S F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. J Nucl Med; 60(7):910-6).
  • 68 Ga or 18 F e.g. [ 68 Ga]Ga-PSMA-ll,
  • the Phase-I study also demonstrated that metastatic lesions are detected with higher sensitivity on [ 18 F]CTT1057 imaging than on conventional imaging (Behr et al 2019).
  • Another smaller study showed that the image quality on [ 18 F]CTT1057 PET imaging was qualitatively similar to that obtained on [ 68 Ga]Ga-PSMA- 11 PET (Behr S, Aggarwal R, Flavell R, et al (2017) [abstract]. J Nucl Med; 58 Suppl 1:733A).
  • the present disclosure provides novel methods of use of PET imaging agents for detection and localization of PSMA positivity in patients diagnosed of biochemical recurrence, in particular in patients with prostate cancer.
  • an objective of the present disclosure is to provide methods of detecting PSMA- positive tumors using PET imaging agents with a high affinity towards a target on PSMA- expressing cancer cells, preferably prostate cancer cells providing very high tumor-to- background ratios.
  • the present disclosure thus relates to a radioligand imaging agent, for use in determining the presence and/or localization of PSMA-positive tumors in a subject, wherein said subject has been diagnosed with biochemical recurrence, and wherein said radioligand imaging agent is a PSMA-binding compound comprising a phosphoramidate group and a [ 18 F]-fluoro group.
  • the disclosure also relates to a solution for injection or infusion, which is an aqueous solution comprising a PSMA-binding compound comprising a phosphoramidate group and a [ 18 F]- fluoro group, in a concentration providing a volumetric radioactivity between 150 and 1000 MBq/mL, for example about 370 MBq/mL, and one or more pharmaceutically acceptable excipients.
  • PSMA-positive tumor refers to a tumor lesion which can be detected with a tracer compound comprising a PSMA-binding moiety, typically a radioligand imaging agent such as the 18 F radiolabeled PSMA-binding compound of formula (I), (II) or (III) as described below.
  • a tracer compound comprising a PSMA-binding moiety
  • a radioligand imaging agent such as the 18 F radiolabeled PSMA-binding compound of formula (I), (II) or (III) as described below.
  • PET positron-emission tomography
  • SPECT single-photon emission computed tomography
  • MRI magnetic resonance imaging
  • CT computed tomography
  • the terms “effective dose” of a radioligand imaging agent for use according to the methods of the disclosure refer to an amount of the imaging agent that is sufficient for determining the presence or localisation of PSM A-positive lesions in a patient from an imaging study using said imaging agent. In particular, in specific embodiments, the presence and/or localisation is more reliably determined with the methods of the present disclosure than conventional imaging methods.
  • An effective dose may be determined by the radioactivity of the injected solution at injection time.
  • the radioactivity of the injected solution may be derived from the measurement of the volumetric radioactivity of the solution for injection at a reference time, typically, after production of the solution for injection, also referred as the “calibration time”. The physician will adjust the volume to be injected based on the estimated volumetric radioactivity at injection time and the known volumetric radioactivity at calibration time.
  • the term “calibration time” when referring to the radioactivity of the volumetric radioactivity of a composition refers to the radioactivity measured at a reference date and time, for example, within 60 minutes after the product manufacturing.
  • Radiochemical purity is that percentage of the stated radionuclide that is present in the stated chemical or biological form. Radiochromatography methods, such as HPLC method or Thin Layer Chromatography method (TLC), are commonly accepted methods for determining radiochemical purity in the radiopharmacy. In specific embodiments, the radiochemical purity of the radioligand imaging agent is superior or equal to 95%.
  • aqueous solution refers to a solution of one or more solute in water.
  • the term “aqueous solution” may also refer to hydroalcoholic solution, including water and an alcohol, preferably ethanol, for example alcohol is comprised between 0% and 20%, preferably between 0% and 10%, for example between 2% and 8%, and more preferably about 5%.
  • heteroalkylene refers to a divalent heteroalkyl, which is a straight or branched hydrocarbon chain consisting of 1 to 35 carbon atoms, preferably 1 to 20, and from 1 to 15 heteroatoms selected from the group consisting of O, N and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized (for example: a sulfoxide or a sulfone) and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkylene group and at either or both of the chain termini.
  • the radioligand imaging agent for use in the methods of the disclosure
  • the radioligand imaging agent for use according to the present disclosure is a PSMA-binding compound comprising at least a phosphoramidate group and a [ I8 F]-fluoro group, or any pharmaceutically acceptable salts thereof.
  • l8 F radiolabeled PSMA-binding compounds have been described in the art, and include those described in WO2013173583 or WO2014143736.
  • the radioligand imaging agent for use according to the present disclosure is a PSMA-binding compound of formula (I): pharmaceutically acceptable salts thereof wherein each R is independently hydrogen or a protecting group (e.g t-butyl or benzyl), each R2 is independently hydrogen or C1-C6 alkyl,
  • R3 is a phenyl or pyridyl, each substituted with [ 18 F]-fluoro group and optionally substituted with a second group selected from the group consisting of halo, cyano and nitro
  • LI is a linker preferably comprising one or more groups selected from one or more amino- acids, Cl -Cl 8 alkylene, and heteroalky lene comprising 1 to 35 carbon atoms and 1 to 15 heteroatoms, said heteroalkylene being optionally substituted by one or more substituents selected from oxo and C1-C6 alkyl, and more preferably LI is a linker selected from 1 to 6 amino-acids.
  • the radioligand imaging agent for use according to the present disclosure is a PSMA-binding compound of formula (II): or any pharmaceutically acceptable salts thereof, wherein L is a linker comprising a moiety of the formula -NH-CH 2 CH 2 -(0CH 2 CH 2 -)y-C(0)- or a group of the formula wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12: m is 1, 2, 3, or 4; Each n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
  • R1 is a phenyl or pyridyl, each substituted with [ I8 F]-fluoro group and optionally substituted with a second group selected from the group consisting of chloro and cyano;
  • Each R2 is independently hydrogen or C1-C6 alkyl; and each R is independently hydrogen or a protecting group (e.g t-butyl or benzyl). Provided that when L is a group of the formula
  • linker length 3 to 21 atoms.
  • linker length is calculated using the formula m-(n+2).
  • protecting group is a group introduced to a functional group (e.g., an phosphorous acid or carboxylic acid) that allows for chemoselectivity in a subsequent chemical transformation.
  • a functional group e.g., an phosphorous acid or carboxylic acid
  • Such groups specifically carboxylic and phosphorus acid protecting groups, are described in Greene's Protective Groups in Organic Synthesis, 4th Edition (the relevant parts of which are incorporated by reference).
  • a "protecting group” is alkyl, alkenyl, or haloalkyl. This includes, but is not limited to: methyl, ethyl, propyl, isopropyl, tert-butyl, allyl, trifluoromethyl or trifluoroethyl.
  • a "protecting group” is benzyl or substituted benzyl, which includes, but is not limited to, triphenylmethyl (trityl), diphenylmethyl, o-nitrobenzyl, 2,4,6-trimethylbenzyl, p-bromobenzyl, p-nitrobenzyl, p- methoxybenzyl (PMB), 2,6- dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4-sulfobenzyl, 4- azidomethoxybenzyl, and piperonyl.
  • the radioligand imaging agent for use according to the present disclosure is the PSMA-binding compound of formula (III): or any pharmaceutically acceptable salts thereof.
  • PSMA-binding compounds for use according to the present disclosure and a method of synthesis of such compounds have been described in particular in WO2014/143736 which content is incorporated hereby in its entirety.
  • the PSMA-binding compound for use according to the present disclosure may be synthesized from the precursor CTT1298 of formula (IV) below, in particular, by coupling succinimidyl- 18 F-fluorobenzoate to the primary amine precursor as described in the following reaction scheme.
  • [ I8 F]SFB may be synthesized through the following reaction scheme:
  • the PSMA-binding compound for use according to the present disclosure is formulated as a pharmaceutical composition, typically a solution for injection or infusion.
  • Said solution for injection or infusion is preferably an aqueous or hydro- alcoholic solution which comprises the PSMA-binding compound as described herein, and one or more pharmaceutically acceptable excipients.
  • said PSMA-binding compound can be present in said pharmaceutical composition in a concentration providing a volumetric radioactivity between 150 and 1000 MBq/mL, preferably 200 and 700 MBq/mL, more preferably 250 and 450 MBq/mL, for example about 370 MBq/mL at calibration time.
  • the pharmaceutically acceptable excipient(s) can be any of those conventionally used.
  • the one or more excipients can be selected from buffers, stabilizers against radiolytic degradation, isotonic agents, and mixtures thereof.
  • stabilizer against radiolytic degradation refers to stabilizing agent which protects organic molecules against radiolytic degradation, e.g. when a gamma ray emitted from the radionuclide is cleaving a bond between the atoms of an organic molecules and radicals are forms, those radicals are then scavenged by the stabilizer which avoids the radicals undergo any other chemical reactions which might lead to undesired, potentially ineffective or even toxic molecules. Therefore, those stabilizers are also referred to as “free radical scavengers” or in short “radical scavengers”. Other alternative terms for those stabilizers are “radiation stability enhancers”, “radiolytic stabilizers”, or simply “quenchers“. In preferred embodiment, a stabilizer against radiolytic degradation is ethanol.
  • Buffers include phosphate, acetate or citrate buffer or their combinations, preferably phosphate buffer.
  • the buffer or combination of buffers is suitable for a pH between 6.5 and 7.5.
  • Isotonic agents include sodium chloride, in particular at a concentration of about 0.9%.
  • said solution for injection or infusion comprises the radioligand imaging agent as described in the previous section, for example, a PSMA-binding compound of formula (I), (II) or (III), preferably the compound of formula (III), at a concentration providing a volumetric radioactivity between 150 and 1000 MBq/mL, preferably 200 and 700 MBq/mL, more preferably 250 and 450 MBq/mL, at calibration time, typically about 370 MBq/mL at calibration time, and, optionally, a phosphate buffer and sodium chloride.
  • a PSMA-binding compound of formula (I), (II) or (III) preferably the compound of formula (III)
  • at a concentration providing a volumetric radioactivity between 150 and 1000 MBq/mL, preferably 200 and 700 MBq/mL, more preferably 250 and 450 MBq/mL, at calibration time, typically about 370 MBq/mL at calibration time, and, optionally, a phosphate buffer and sodium chloride.
  • the solution for injection or infusion further comprises a buffer for a pH between 6.5 and 7.5, preferably phosphate buffer, and an isotonic agent, preferably sodium chloride.
  • a buffer for a pH between 6.5 and 7.5 preferably phosphate buffer
  • an isotonic agent preferably sodium chloride.
  • the solution may further comprise a maximum amount of the precursor compound as used for synthesis.
  • the precursor compound of formula (IV) (also referred as CTT1298) is present in a concentration of not more than 5 mg/mL, preferably not more than 4 pg/mL, more preferably not more than 3 pg/mL, even more preferably not more than 2 pg/mL, even more preferably not more than 1 pg/mL.
  • the solution may further comprise a stabilizer against radiolysis that may be suitable as an eluent during the manufacturing of the solution, preferably said stabilizer and/or eluent is an alcohol, preferably ethanol.
  • a stabilizer against radiolysis may be suitable as an eluent during the manufacturing of the solution, preferably said stabilizer and/or eluent is an alcohol, preferably ethanol.
  • the solution for injection therefore comprises
  • the radioligand imaging agent as described in the previous section, for example, a PSMA-binding compound of formula (I), (II) or (III), preferably the compound of formula (III), in a concentration providing a volumetric radioactivity between 250 and 450 MBq/mL at calibration time, typically at about 370 MBq/mL at calibration time,
  • Na2HP04 in a concentration from 0.2 to 1.2 mg/mL; preferably from 0.3 and 1.1 mg/mL;
  • ethanol in a concentration from 5 - 50 mg/mL; preferably from 10.0 and 39.5 mg/mL;
  • a precursor compound for example the CTT1298 precursor compound of formula IV
  • a concentration of not more than 5.0 mg/mL preferably not more than 4.0qg/mL, even more preferably not more than 3.0mg/mL, even more preferably not more than 2.0qg/mL, preferably not more than 1.0mg/mL.
  • the detection methods and use of the radioligand imaging agent according to the present disclosure are intended for subjects with biochemical recurrence, preferably for subjects with prostate cancer with biochemical recurrence.
  • the detection methods and use of the radioligand imaging agent according to the present disclosure are intended for subjects with prostate cancer with biochemical recurrence after radical prostatectomy or after radiotherapy.
  • biochemical recurrence refers to its general meaning as proposed by the American Urological Association criteria. More specifically, a definition of biochemical recurrence after radical prostatectomy is provided in Cookson et al 2007 J Urol;177(2):540-5. In specific embodiments, it relates to a subject with prostate cancer having undergone radical prostatectomy and with detectable or rising of PSA level measured 6-13 weeks after surgery, that is superior or equal to 0.2 ng/ml, and optionally with a second confirmatory level, measured at least two weeks after the first measurement, which is strictly superior to 0.2 ng/ml.
  • a definition of a subject with biochemical recurrence after radiotherapy may be provided by Roach et al 2006 Int J Radiat Oncol Biol Phys;65(4):965-74. In specific embodiments, it relates to a subject who have undergone curative intent radiotherapy with biochemical recurrence defined by American Society for Radiation Oncology (ASTRO)-Phoenix criteria (PSA superior or equal to 2ng/ml above the nadir PSA, defined as the lowest PSA achieved (PSA nadir + 2)).
  • ASTRO American Society for Radiation Oncology
  • PSA superior or equal to 2ng/ml above the nadir PSA, defined as the lowest PSA achieved (PSA nadir + 2) The methods for determining the presence and localization of positive tumors in a subject with biochemical recurrence
  • An objective of the present disclosure is to provide methods for determining the presence or localization of PSMA-positive tumors in a subject with biochemical recurrence, typically in a subject with prostate cancer.
  • the presence and localization of PSMA-positive tumors is detected by analyzing the uptake of the PSMA-binding compound after injection of a radiotracer, for example, the PSMA- binding compound, in said subject which has been diagnosed with biochemical recurrence.
  • a radiotracer for example, the PSMA- binding compound
  • the disclosure relates to a method for determining the presence and/or the localization of PSMA positive tumors in a subject, wherein said subject has been diagnosed with biochemical recurrence, said method comprising
  • a radioligand imaging agent as described above, preferably a PSMA-binding compound of formula (I), (II) or (III), and most preferably a PSMA-binding compound of formula (III) below or any pharmaceutically acceptable salts thereof,
  • PET scan for example PET/CT or PET/MRI scan
  • the disclosure relates to a method for determining the presence and/or the localization of PSMA positive tumors in a subject with prostate cancer, wherein said subject has been diagnosed with biochemical recurrence, typically after radical prostatectomy or after radiotherapy, said method comprising [i] administering to said subject, an effective dose of a radioligand imaging agent as described above, preferably a PSMA-binding compound of formula (I), (II) or (III), and most preferably a PSMA-binding compound of formula (III) below or any pharmaceutically acceptable salts thereof,
  • PET scan for example PET/CT or PET/MRI scan
  • an effective dose is an amount of the imaging agent sufficient to yield an acceptable image using equipment which is available for clinical use.
  • the amount of imaging agent used for the methods of the disclosure and the duration of the imaging step will depend upon, inter alia the body mass of the patient, the nature and severity of the condition to be detected, the nature of the therapeutic treatments which the patients has undergone, etc.
  • the physician may decide the amount of the imaging agent to administer to each individual patient and the duration of the imaging step.
  • a subject diagnosed with biochemical recurrence receives a single effective dose of 250-450 MBq, typically about 370 MBq, by intravenous injection of a solution for injection or infusion comprising said radioligand imaging agent as described above.
  • the volume of injection does not exceed 10 mL, for example is comprised between 500 pL and lOmL, preferably 800 pL pL and 5 mL, for example between 800 pL and 2 mL, and preferably about 1 mL.
  • Images of patient’s body are then acquired by positron emission tomography - magnetic resonance imaging (PET/MRI) or positron emission tomography - computed tomography (PET/CT) imaging.
  • PET/MRI positron emission tomography - magnetic resonance imaging
  • PET/CT positron emission tomography - computed tomography
  • Methods for acquisition of image by PET/MRI or PET/SCAN are well- known in the art.
  • the first PET scan is performed with a window from 60-120 minutes post injection/infusion, for example at 90 minutes, with a possibility of a second PET scan performed up to 180 minutes after injection of the radioligand imaging agent.
  • Images are then analyzed, either by visual assessment, quantitative assessment or both, to identify the presence of one or more PSMA-positive lesions, and/or to determine the localization of one or more PSMA-positive lesions.
  • Images can be generated by virtue of differences in the spatial distribution of the imaging agents which accumulate at a site when contacted with PSMA.
  • the spatial distribution may be measured using any means, for example, the PET apparatus.
  • the extent of accumulation of the imaging agent may be quantified using known methods for quantifying radioactive emissions.
  • a particularly useful imaging approach may employ more than one imaging agent to perform simultaneous studies.
  • PSMA-positive tumors or “PSMA-positive lesions” refers to lesions visually identified in subject, preferably in subject with prostate cancer, to show pathological radioligand imaging agent uptake on PET/CT or PET/MRI as follows: ⁇ Visually PET positive lymph nodes considered greater than blood pool (adjacent or mediastinal blood pool);
  • the subject with biochemical recurrence has no PSMA- positive lesions detected by conventional imaging.
  • the methods are expected to show improved sensitivity and/or specificity for detection of PSMA-positive tumor as compared to [ 68 Ga]-PSMA-ll compound, in particular in subject with prostate cancer with biochemical recurrence.
  • 18 F-labeled tracers have the following practical advantages: 18 F has a longer half-life than 68 Ga, which enables the tracers to be distributed to PET centers without a cyclotron and to be easily handled in clinical routine.
  • the method is useful in particular in management of patients for treating the recurrence.
  • the present disclosure also relates to a method for monitoring the disease state of a subject with biochemical recurrence, said method comprising
  • a radioligand imaging agent as described above, for example, a PSMA-binding compound of formula (I), (II) or (III) or any pharmaceutically acceptable salts thereof, and more preferably a PSMA-binding compound of formula (III) below or any pharmaceutically acceptable salts thereof, preferably by intravenous injection of a solution of injection as described previously,
  • PET positron emission tomography
  • treatment options may subsequently change among different approaches such as Surgery, Radiation alone, Radiation plus androgenic deprivation therapy, androgenic deprivation therapy alone, Observation/surveillance, or other.
  • the disclosure further relates to a kit for monitoring the disease state of a subject as described above, said kit comprising at least an effective dose of a radioligand imaging agent as described above, for example a PSMA-binding compound of formula (I), (II) or (III) and more preferably a PSMA binding compound of formula (III) below or any of its pharmaceutically acceptable salts thereof, or a solution for injection or infusion comprising said radioligand imaging agent as described previously.
  • a radioligand imaging agent as described above, for example a PSMA-binding compound of formula (I), (II) or (III) and more preferably a PSMA binding compound of formula (III) below or any of its pharmaceutically acceptable salts thereof, or a solution for injection or infusion comprising said radioligand imaging agent as described previously.
  • kits for use of the methods as above described comprising an effective dose, for example about 370 MBq of the radioligand imaging agent or their precursors for the synthesis as described above, in combination with a pharmaceutically acceptable carrier.
  • an effective dose for example about 370 MBq of the radioligand imaging agent or their precursors for the synthesis as described above, in combination with a pharmaceutically acceptable carrier.
  • the imaging agent, their precursors and the carrier are provided in solutio
  • a kit for use in the methods of the present disclosure comprises a non- radiolabeled precursor, typically the compound of formula (IV), to be combined with a radiolabeled reagent on-site, such as K[ I8 F] or Na[ 18 F].
  • a radiolabeled reagent on-site such as K[ I8 F] or Na[ 18 F].
  • a radioligand imaging agent for use in a diagnostic method for determining the presence and/or localization of PSMA-positive tumors in a subject, particularly said subject is a subject with prostate cancer, and said PSMA-positive tumors is prostate cancer, wherein said subject has been diagnosed with biochemical recurrence, and wherein said radioligand imaging agent is a PSMA-binding compound comprising a phosphoramidate group and a [ l8 F]-fluoro group.
  • E2 The radioligand imaging agent for use according to El or Elb, where said agent is a PSMA- binding compound of formula (I): or any pharmaceutically acceptable salts thereof, wherein each R is independently hydrogen or a protecting group (e.g t-butyl or benzyl).
  • each R2 is independently hydrogen or C1-C6 alkyl
  • R3 is a phenyl or pyridyl, each substituted with [ I8 F]-fluoro group and optionally substituted with a second group selected from the group consisting of halo, cyano and nitro
  • LI is a linker, preferably comprising one or more groups selected from one or more amino- acids, Cl -Cl 8 alkylene, and heteroalky lene comprising 1 to 35 carbon atoms and 1 to 15 heteroatoms, said heteroalkylene being optionally substituted by one or more substituents selected from oxo and C1-C6 alkyl, and more preferably LI is a linker selected from 1 to 6 amino-acids.
  • radioligand imaging agent for use according to any one of El, E lb or E2, where said radioligand imaging agent is a PSMA-binding compound of formula (II): and any pharmaceutically acceptable salts thereof, wherein
  • L is a linker comprising a moiety of the formula -NH-CH 2 CH 2 -(OCH 2 CH 2 -)y-C(0)- or a group of the formula wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12: m is 1, 2, 3, or 4; each n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
  • R1 is a phenyl or pyridyl, each substituted with [ I8 F]-fluoro group and optionally substituted with a second group selected from the group consisting of halo, cyano and nitro; each R2 is independently hydrogen or C1-C6 alkyl; and each R is independently hydrogen or a protecting group (e.g t-butyl or benzyl)
  • E4 The radioligand imaging agent for use according to any one of E1-E3, wherein said radioligand imaging agent is the PSMA-binding compound of formula (III): or any pharmaceutically acceptable salts thereof.
  • E5 The radioligand imaging agent for use according to any one of E1-E4, wherein said subject has been diagnosed with biochemical recurrence after radical prostatectomy or radiotherapy.
  • E6 The radioligand imaging agent for use according to any one of E1-E5, wherein said radioligand imaging agent is formulated as a solution for injection or infusion in a concentration providing a volumetric radioactivity from 150 to 1000 MBq/mL, for example 370 MBq/mL +/- 10% at calibration time.
  • E7 The radioligand imaging agent for use according to any one of E1-E6, wherein said radioligand imaging agent is administered intravenously at an effective dose comprised between 250 and 450 MBq, typically about 370 MBq.
  • E8 The radioligand imaging agent of E6 or E7, wherein a first PET scan imaging of the subject is performed between 60 and 120 minutes post-injection or infusion, and optionally a second scan imaging is performed up to 180 minutes post-injection or infusion.
  • a solution for injection or infusion which is an aqueous solution comprising said radioligand imaging agent as defined in any of Ed -E5, in a concentration providing a volumetric radioactivity between 150 and 1000 MBq/mL, for example about 370 MBq/mL, and one or more pharmaceutically acceptable excipients.
  • Ell The solution of E9 or E10, further comprising a buffer for a pH between 5.0 and 8.0, preferably between 6.0 and 8.0, more preferably between 6.5 and 7.5, preferably phosphate buffer, and an isotonic agent, preferably sodium chloride.
  • a buffer for a pH between 5.0 and 8.0 preferably between 6.0 and 8.0, more preferably between 6.5 and 7.5
  • an isotonic agent preferably sodium chloride.
  • El 2 The solution of Ell, further comprising a stabilizer against radiolysis, preferably a stabilizer that is suitable as an eluent during the manufacturing of the solution, preferably said stabilizer and/or eluent is an alcohol, preferably ethanol.
  • E13 The solution of El 2, comprising
  • E14 A method for determining the presence and/or the localization of PSMA positive tumors in a subject, preferably a subject with prostate cancer, wherein said subject has been diagnosed with biochemical recurrence, said method comprising
  • E16 The method of E14 or E15, which determines the presence and/or the localization of PSMA positive tumor lesions of a size from 5 to 10 mm.
  • E17 The method of E14-E16, wherein the step (ii) of imaging comprises a first PET scan performed from 60 to 120 minutes post injection/infusion, typically about 90 minutes post injection/infusion, and optionally a second PEiT scan is performed up to 180 minutes post injection/infusion.
  • E18 The method of any one of E14-E17, wherein said radioligand imaging agent is formulated as a solution for injection or infusion as defined in any one of embodiments E9-E13.
  • E19 A method for monitoring the disease state of a subject with biochemical recurrence, said method comprising
  • a radioligand imaging agent as described above, for example, a PSMA-binding compound of formula (I), (II) or (III) or any pharmaceutically acceptable salts thereof, and more preferably a PSMA-binding compound of formula (III) below or any pharmaceutically acceptable salts thereof, preferably by intravenous injection of a solution of injection as described previously,
  • PET positron emission tomography
  • E21 The method of E20, wherein said subject has been diagnosed with biochemical recurrence after radical prostatectomy or radiotherapy.
  • a process for manufacturing a radioligand imaging agent for use in a diagnostic method comprising the steps as defined in any one of ET4-18, wherein said radioligand imaging agent is as defined in any of E1-E9.
  • E23 A solution for injection or infusion, which is an aqueous solution comprising a radioligand imaging agent being a PSMA-binding compound comprising a phosphoramidate group and a [ 18 F]-fluoro group, in a concentration providing a volumetric radioactivity between 150 and 1000 MBq/mL, for example about 370 MBq/mL, and one or more pharmaceutically acceptable excipients.
  • E24 The solution of E23, wherein said radioligand imaging agent is a PSMA-binding compound of formula (I): or any pharmaceutically acceptable salts thereof, wherein each R is independently hydrogen or a protecting group (e.g t-butyl or benzyl) each R2 is independently hydrogen or C1-C6 alkyl,
  • each R is independently hydrogen or a protecting group (e.g t-butyl or benzyl)
  • each R2 is independently hydrogen or C1-C6 alkyl
  • R3 is a phenyl or pyridyl, each substituted with [ 18 F]-fluoro group and optionally substituted with a second group selected from the group consisting of halo, cyano and nitro
  • LI is a linker, preferably comprising one or more groups selected from one or more amino- acids, Cl -Cl 8 alkylene, and heteroalkylene comprising 1 to 35 carbon atoms and 1 to 15 heteroatoms, said heteroalkylene being optionally substituted by one or more substituents selected from oxo and C1-C6 alkyl, and more preferably LI is a linker selected from 1 to 6 amino-acids.
  • E25 The solution according to any one of E23 or E24, wherein said radioligand imaging agent is a PSMA-binding compound of formula (II): and any pharmaceutically acceptable salts thereof, wherein
  • L is a linker comprising a moiety of the formula -NH-CH 2 CH 2 -(0CH 2 CH 2 -)y-C(0)- or a group of the formula wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12: m is 1, 2, 3, or 4; each n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; R1 is a phenyl or pyridyl, each substituted with [ I8 F]-fluoro group and optionally substituted with a second group selected from the group consisting of halo, cyano and nitro; each R2 is independently hydrogen or C1-C6 alkyl; and each R is independently hydrogen or a protecting group (e.g t-butyl or benzyl) Provided that when L is a group of the formula the combination of m and n result in a linear linker length of 3 to 21 atoms.
  • y 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12
  • m is 1,
  • E26 The solution according to any one of E23-E25, wherein said radioligand imaging agent is the PSMA-binding compound of formula (III): or any pharmaceutically acceptable salts thereof.
  • E27 The solution according to any one of E23-E26, in which a precursor compound of formula (IV) is present in a concentration of not more than 5.0 mg/mL, preferably not more than 4.0 mg/mL, more preferably not more than 3.0 mg/mL, even more preferably not more than 2.0 mg/mL, even more preferably not more than 1.0 mg/mL.
  • E28 The solution according to any one of E23-E27, further comprising a buffer for a pH between 5.0 and 8.0, preferably between 6.0 and 8.0, more preferably between 6.5 and 7.5, preferably phosphate buffer, and an isotonic agent, preferably sodium chloride.
  • E29 The solution according to any one of E23-E28, further comprising a stabilizer against radiolysis, preferably a stabilizer that is suitable as an eluent during the manufacturing of the solution, preferably said stabilizer and/or eluent is an alcohol, preferably ethanol.
  • E30 The solution of E29, comprising
  • Example 1 Manufacturing of a solution comprising the radioligand imaging agent
  • the Drug Product is a diluted solution of the [ 18 L]CTT1057 concentrated mother solution (radioactive drug substance, 15 + 1 mL, with about 1685-6667 MBq/mL at Tm) in NaCl 0.9% to adjust the volumic activity of the final solution at 370 MBq/mL + 10% (Tc).
  • the volume of saline added is calculated according to the activity of [ I8 L]CTT1057 obtained at the end of the synthesis (Tm), decay corrected at the time of calibration (Tc).
  • Tm is the time of measurement of the activity in the mother solution.
  • Tm is some minutes after the EOS.
  • the final volume of drug product ranges between 15 - 59 mL, and the quantitative composition of [ 18 L]CTT1057 finished product varies accordingly.
  • **This amount includes water for injection present in the 25mL vial (0.20 + 0.02 mL) and in the primary packaging vial 15ml (0.10 + 0.01 mL), which is introduced during the sterilization process in amounts that are considered negligible.
  • [ 18 F]SFB prosthetic group is prepared in a one-pot, three-step procedure, starting with a radiofluorination of the LB starting material, followed by a saponification of the ethyl esther and a coupling with TSTU.
  • a two-step purification process drives to the separation of by-products and residual reagents and the final formulated [ 18 F]CTT1057, of a radiochemical purity >95%, is obtained.
  • the radionuclide is obtained in the form of [ 18 F]fluoride ions by bombardment of > 97% pure [ 18 0]water with an intensive beam of accelerated protons. This nuclear reaction is produced in a cyclotron target.
  • [ 18 F]SFB prosthetic group is prepared in a one-pot, three-step procedure, comprising the radiofluorination of the FB precursor starting material to Et-4-[ 18 F]FB, then the saponification of the ethyl esther to obtain [ I8 F]FBA and the coupling of [ I8 F]FBA with TSTU (N,N,N',N'- Tetramethyl-0-(N-succinimidyl)uronium tetrafluoroborate) to [ 18 F]SFB.
  • TSTU N,N,N',N'- Tetramethyl-0-(N-succinimidyl)uronium tetrafluoroborate
  • [ 18 F]SFB N-succinimidyl-4-[18F]fluorobenzoate
  • [ 18 F]SFB is retained in the cartridge while non-reacted [ 18 F]fluoride is moved to the waste.
  • Coupling to CTT1298 - [ 18 F]SFB is eluted from the HLB, in the second reactor, containing CTT1298 solution.
  • the reaction is carried out in the second reactor at 40 °C during 12 min.
  • CTT1057 purification the crude is diluted in water and two-step purification process drives to the separation of by-products and residual reagents. Diluted crude is passed through a QMA cartridge towards the waste. [ 18 L]CTT1057 is retained in the QMA, together with other undesired species. The QMA is rinsed with a solution 0.09% NaCl / 20% EtOH to waste, and [ 18 L]CTT1057 eluted with 20 mM phosphate buffer at pH 2.0 and trapped again onto the HLB in a time-controlled step to minimize the decomposition of [ l8 L]CTT1057 in acidic media.
  • CTT1057 formulation The pure, final formulated [ 18 L]CTT1057 is eluted, neutralized and formulated from the HLB in one single step by a 5% ethanol in pH 7.4 phosphate buffered saline solution formulation solution. Manufacturing process development
  • the drug substance [ l8 F]CTT1057 was developed in a one-step reaction between the prosthetic group [ I8 F]SFB and the chemical precursor CTT1298.
  • non-radioactive [ I9 F]SFB and CTT1298 were used and several coupling reaction conditions were tested: different buffered media over a range of pH from 7 to 11, temperatures from ⁇ 25°C to 60°C, and duration from 5 to 10 minutes.
  • the final adjustment of the time of reaction was optimized using [ 18 F]CTT1057 productions to have the real concentrations condition and to take into account the reaction time versus decay balance.
  • the final purification step of [ I8 F]CTT1057 on SPE cartridge(s) was key to deliver a product with adequate purity.
  • the reaction crude in basic media was diluted and first purified with a QMA (Quaternary Methyl Ammonium) cartridge that allowed removal of most of the radiochemical impurities.
  • QMA Quaternary Methyl Ammonium
  • the Drug Product is a diluted solution of the [ 18 F]CTT1057 concentrated mother solution (radioactive drug substance, 15 + 1 mL) in NaCl 0.9% to adjust the volumic activity of the final solution at 370 MBq/mL + 10% (Tc).
  • the volume of saline added is calculated according to the activity of [ 18 F]CTT1057 obtained at the end of the synthesis (Tm), decay corrected at the time of calibration (Tc).
  • the final volume of drug product ranges between 15 - 59 mL, and the quantitative composition of [ l8 F]CTT1057 finished product varies accordingly.
  • the qualitative and quantitative composition of the drug product in the nominal volumes of 15 mL and 59 mL are described in Table 2.
  • the 25 mL vial is weighed.
  • the net weight of [ I8 F]CTT1057 bulk concentrated mother solution is defined by the difference between the weight of the product vial and the empty vial.
  • the activity contained in the vial is measured with dose calibrator.
  • CRO Contract Research Organization
  • Imaging diagnostic procedures performed on each patient as clinically indicated per SoC which must include at least a high resolution CT scan with contrast and a [ 68 Ga]Ga-PSMA-ll PET/CT performed within 8 weeks (either before or after) the [ I8 F]CTT1057 PET/CT scan.
  • Three-month follow-up imaging (from baseline) will also be used as part of the CTS level 2 in cases where it is clinically required for the diagnosis of particular lesion(s); OR if neither of the two above are feasible or deemed appropriate:
  • a questionnaire on the planned patient management will be filled-in by the treating physician/Clinical Study Investigator before (questionnaire 1) and within 14 days after (questionnaire 2) knowing the results of the [ 18 F]CTT1057 PET/CT scan.
  • a local review of [ l8 F]CTT1057 PET/CT images will also be performed by a local nuclear medicine physician or radiologist with expertise in reading oncology PET/CT scans and the results will be provided to the treating physician/Clinical Study Investigator for completion of questionnaire 2.
  • Options will be given in the questionnaire to capture possible management plan, such as a) Surgery, b) Radiation alone, c) Radiation plus ADT, d) ADT alone, e) Observation/surveillance, f) Other (free text box).
  • ICF Written informed consent form
  • the participant must be registered in the Interactive Response Technology (IRT) for screening. All procedures described in the Assessment Schedule must be carried out, prioritizing laboratory and imaging assessments to allow time to obtain the results at least 14 days prior the planned first PET imaging day (Day 1). Eligibility must then be confirmed at the latest on Day -14.
  • the screening period should last up to 28 days.
  • the participants will be randomized in IRT to be assigned to one of the following two PET/CT scan sequences at random in a 1:1 ratio:
  • Sequence 1 [ IS F]CTT1057 on Day 1 (investigational imaging agent of interest) followed by [ 68 Ga]Ga-PSMA- 11 at least 14 days apart (as part of CTS if required, and for secondary endpoint)
  • the 2 PET imaging procedures will be done at least 14 days apart. The day of the first PET imaging agent injection will be considered study Day 1. Study Design
  • the criteria to be applied for PET positivity is the following:
  • a patient will be judged positive if at least one lesion in any region (i.e. prostate bed, Pelvic Lymph Node (PLN), skeleton, and other distant sites (extra-pelvic lymph nodes and viscera)) is visually positive.
  • PPN Pelvic Lymph Node
  • skeleton skeleton
  • extra-pelvic lymph nodes and viscera other distant sites
  • a region will be judged as positive if at least one lesion in the region is visually positive.
  • PET positive bone lesions will be considered greater than physiologic bone marrow
  • PET positive prostate, prostate bed and visceral lesions will be considered greater than physiologic background activity of the involvement organ or anatomic site, as previously described (Eiber et al 2015 Evaluation of Hybrid 68 Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med; 56(5):668- 74, Ceci et al 2015 (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging; 42:1284-94, Fendler et al 2019 Assessment of 68Ga-PSMA-ll PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol; 5(6):856-63
  • Consistency of the PET scan interpretation both between different readers and within readers is an important issue in medical imaging, as it affects portability of results between institutions and may affect patient care.
  • the degree of inter- and intra-reader variability in the qualitative assessment of [ I8 F]CTT1057 PET/CT images will be assessed as a secondary endpoint to ensure consistency of interpretation and hence reliable diagnosis, which has pivotal role in the patient management.
  • All patients will undergo 2 PET/CT scans: a [ I8 F]CTT1057 PET/CT scan (investigational imaging agent) and a [ 68 Ga]Ga-PSMA-l 1 PET/CT scan (as part of the CTS level 2 if required, and for the secondary endpoint of assessment of concordance between [ I8 F]CTT1057 and [ 68 Ga]Ga-PSMA- 11 for detection of lesions at patient level).
  • the two scans will be performed at least 2 weeks apart for each participant in order to ensure a clean safety profile assessment for each PET imaging radiopharmaceutical.
  • the PET/CT scan sequence for each patient will be assigned at random, in a 1:1 ratio after enrolment.
  • the investigational PET radiopharmaceutical [ 18 F]CTT1057 will be administered accordingly, as a single intravenous (i.v.) dose of approximately 370 MBq (266 - 407 MBq). This dose was shown to be safe and well tolerated in the Phase I study (Behr et al 2019 Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate- Specific Membrane Antigen in Prostate Cancer.
  • the effective dose was estimated at 0.023+0.007 mSv/MBq, which is in line as well with the effective dose of the commercial product [18F]FDG (0.019 mSv/MBq) according to the EANM guideline (Boellaard R, Delgado-Bolton R, Oyen WJG, et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging; 42:328-54) and in other publications (0.020-0.025 mSv/MBq) (Kaushik A, Jaimini A, Tripathi M, et al (2015) Estimation of radiation dose to patients from (18) FDG whole body PET/CT investigations using dynamic PET scan protocol.
  • PSMA-PET scanning of prostate cancer participants has been ongoing since 2011, mostly with [ 68 Ga]Ga-PSMA-ll, to assess disease burden in the setting of both biochemical recurrence (BCR) and advanced/metastatic disease.
  • BCR biochemical recurrence
  • Publications that report clinical use have demonstrated better sensitivity and specificity than choline-based PET imaging for PCa, with a very low rate of adverse events.
  • [ 68 Ga]Ga-PSMA- 11 has been approved in the USA (December 2020) as a radioactive diagnostic PET imaging agent in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or with suspected recurrence based on elevated serum PSA level ([ 68 Ga]Ga-PSMA-ll USPI).
  • PSMA-PET agents have been investigated and are under clinical development, all of them showing a good safety and tolerability profile.
  • Prostate cancer patients diagnosed of localized disease, at primary staging, have been enrolled in studies requiring histopathology comparisons to determine diagnostic yield of the technique.
  • the drug product [ I8 F]CTT1057 370 MBq/mL solution for injection is a sterile ready-to use multidose solution containing [ I8 F]CTT1057 as drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time).
  • the natural decay of the radionuclide leads to a continuous decrease of the specific activity, the total radioactivity and the radioactive concentration of the drug product over time.
  • the radioactive drug substance is [ I8 F]CTT1057, a fluorine ( I8 F) labelled PSMA agent which is produced in an automated continuous process as an aqueous concentrated solution (so called Mother Solution).
  • the mother solution is diluted further, taking into consideration the starting 18 F activity, obtained radiochemical yield and targeted radioactivity concentration of 370 MBq/mL at the calibration time, to the finished product [18FJCTT1057 ready-to-use solution for injection.
  • the composition of the finished product is shown in Table 2 below. Table 2 Composition of [ 18 F]CTT1057 370 MBq/mL solution for injection
  • NaCl and WFI are components of NaCl 0.9% solution for injection and NaH 2 P0 4 is used as a dihydrated salt form.
  • the [ I8 F]CTT1057 radiopharmaceutical will be administered intravenously at a dose of approximately 370 MBq (range 266 - 407 MBq).
  • the [ 68 Ga]Ga-PSMA- 11 radiopharmaceutical will be administered as a single intravenous (i.v.) dose of approximately 150 MBq.
  • Administered doses must not be lower than 111 MBq or higher than 185 MBq in any case.
  • the exact dose that will have been administered to each patient will be recorded in the CRF after measurement of the syringe both before and after administration in a dose calibrator.
  • the investigational imaging agent [ 18 F]CTT1057 will be provided: as a single mono-dose syringe (for US) or a single multidose vial (for European Union (EU)) ready to use radiopharmaceutical solution for injection, with a volumetric activity of 370 (+10%) MBq/mL at the reference date and time (calibration time (Tc)).
  • the component [ 68 Ga]Ga-PSMA-l 1 will be provided: as a kit for radiopharmaceutical preparation: single vial with a white lyophilized powder to be locally reconstituted with a solution of gallium-68 chloride ( 68 GaCl3) in HC1 eluted from an approved 68 Ge/ 68 Ga generator (for the clinical sites equipped with an approved 68 Ge/ 68 Ga generator). as a single dose ready to use radiopharmaceutical solution: vial or syringe with the radiopharmaceutical solution supplied by the partner radiopharmacy (for the clinical sites not equipped with an approved 68 Ge/ 68 Ga generator).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PCT/EP2022/058754 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer Ceased WO2022207906A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2023560269A JP2024514293A (ja) 2021-04-02 2022-04-01 前立腺がんの診断方法
KR1020237032903A KR20230165761A (ko) 2021-04-02 2022-04-01 전립선암의 진단 방법
CN202280026305.2A CN117120100A (zh) 2021-04-02 2022-04-01 前列腺癌的诊断方法
IL307381A IL307381A (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer
EP22720606.7A EP4313175A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer
CA3215723A CA3215723A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer
US18/552,760 US20240181092A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21305432 2021-04-02
EP21305432.3 2021-04-02

Publications (1)

Publication Number Publication Date
WO2022207906A1 true WO2022207906A1 (en) 2022-10-06

Family

ID=75588163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/058754 Ceased WO2022207906A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Country Status (9)

Country Link
US (1) US20240181092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313175A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514293A (cg-RX-API-DMAC7.html)
KR (1) KR20230165761A (cg-RX-API-DMAC7.html)
CN (1) CN117120100A (cg-RX-API-DMAC7.html)
CA (1) CA3215723A1 (cg-RX-API-DMAC7.html)
IL (1) IL307381A (cg-RX-API-DMAC7.html)
TW (1) TW202304531A (cg-RX-API-DMAC7.html)
WO (1) WO2022207906A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024216101A1 (en) * 2023-04-12 2024-10-17 Cornell University Radiotherapeutic conjugates for treating cancer
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2014143736A1 (en) 2013-03-15 2014-09-18 Cancer Targeted Technology Llc 18f-labeled psma-targeted pet imaging agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240027896A (ko) * 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2014143736A1 (en) 2013-03-15 2014-09-18 Cancer Targeted Technology Llc 18f-labeled psma-targeted pet imaging agents

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
AFSHAR-OROMIEH AAVTZI EGIESEL FL ET AL.: "The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer", EUR. J. NUCL. MED. MOL. IMAGING, vol. 42, 2015, pages 197 - 209, XP035441273, DOI: 10.1007/s00259-014-2949-6
AFSHAR-OROMIEH ALI ET AL: "The diagnostic value of PET/CT imaging with the68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer", EUROPEAN JOURNAL OF NUCLEAR MEDICINE, SPRINGER VERLAG, HEIDELBERG, DE, vol. 42, no. 2, 20 November 2014 (2014-11-20), pages 197 - 209, XP035441273, ISSN: 1619-7070, [retrieved on 20141120], DOI: 10.1007/S00259-014-2949-6 *
BEHR SAGGARWAL RFLAVELL R ET AL., J NUCL MED, vol. 58, 2017, pages 733A
BEHR SCAGGARWAL RVANBROCKLIN HF ET AL.: "Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer", J NUCL MED, vol. 60, no. 7, 2019, pages 910 - 6, XP055839870, DOI: 10.2967/jnumed.118.220715
BEHR SCAGGARWAL RVANBROCKLIN HF ET AL.: "Phase I Study of CTT1057, an F- Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer", J NUCL MED, vol. 60, no. 7, 2019, pages 910 - 6, XP055839870, DOI: 10.2967/jnumed.118.220715
BEHR SCAGGARWAL RVANBROCKLIN HF ET AL.: "Phase I Study of CTT1057, an F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer", J NUCL MED, vol. 60, no. 7, 2019, pages 910 - 6, XP055839870, DOI: 10.2967/jnumed.118.220715
BEHR SPENCER C. ET AL: "Phase I Study of CTT1057, an 18 F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer", THE JOURNAL OF NUCLEAR MEDICINE, vol. 60, no. 7, 1 July 2019 (2019-07-01), US, pages 910 - 916, XP055839870, ISSN: 0161-5505, DOI: 10.2967/jnumed.118.220715 *
BOELLAARD RDELGADO-BOLTON ROYEN WJG ET AL.: "FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0", EUR J NUCL MED MOL IMAGING, vol. 42, 2015, pages 328 - 54, XP036840886, DOI: 10.1007/s00259-014-2961-x
BOTT, PROSTATE CANCER AND PROSTATIC DIS, vol. 7, 2004, pages 211 - 6
BRAY FREN JSMASUYER E ET AL., INT J CANCER, vol. 132, 2013, pages 1133 - 45
CALAIS ET AL.: "Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer", J NUCL MED, vol. 59, no. 11, 2018, pages 1714 - 21
CECI FUPRIMNY CNILICA B ET AL.: "68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?", EUR J NUCL MED MOL IMAGING, vol. 42, 2015, pages 1284 - 94
CONTI MERIKSSON L, EJNMMI PHYSICS, vol. 3, no. 1, 2016, pages 1 - 17
COOKSON ET AL., J UROL, vol. 177, no. 2, 2007, pages 540 - 5
DELBEKE DCOLEMAN REGUIBERTEAU MJ ET AL.: "Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0", J NUCL MED, vol. 47, no. 5, 2006, pages 885 - 95
EIBER MMAURER TSOUVATZOGLOU M ET AL.: "Evaluation of Hybrid Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy", J NUCL MED, vol. 56, no. 5, 2015, pages 668 - 74, XP055839872, DOI: 10.2967/jnumed.115.154153
EISENHAUER EATHERASSE PBOGAERTS J ET AL.: "New response evaluation criteria in solid tumours: revised RECIST guideline", EUR J CANCER, vol. 45, 2009, pages 228 - 47, XP025841550, DOI: 10.1016/j.ejca.2008.10.026
FENDLER WPCALAIS JEIBER M ET AL.: "Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial", JAMA ONCOL, vol. 5, no. 6, 2019, pages 856 - 63
HAN SWOO SKIM YJ ET AL., EUR UROL, vol. 74, 2018, pages 179 - 90
ISBARN ET AL., BJU INT, vol. 106, 2010, pages 37 - 43
JIVAN ET AL., J LABELLED COMP RADIOPHARM, vol. 60, 2017, pages 1
JIVAN SALMA ET AL: "Fully automated preparation of [18F]CTT1057, a new prostate cancer imaging agent, prepared using the ORA Neptis Perform Synthesizer", 22ND INTERNATIONAL SYMPOSIUM ON RADIOPHARMACEUTICAL SCIENCES, vol. 60 (suppl 1), 14 May 2017 (2017-05-14), pages S140, XP055840223 *
KAUSHIK AJAIMINI ATRIPATHI M ET AL.: "Estimation of radiation dose to patients from (18) FDG whole body PET/CT investigations using dynamic PET scan protocol", INDIAN J MED RES, vol. 142, 2015, pages 721 - 31
MALVEZZI MCARIOLI GBERTUCCIO P ET AL.: "European cancer mortality predictions for the year 2019 with focus on breast cancer", ANN ONCOL, vol. 30, no. 5, 2019, pages 781 - 7
NANNI CZANONI LPULTRONE C ET AL.: "eS)F-FACBC (antil-amino-3-(18)F-fluorocyclobutane-l-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial", EUR J NUCL MED MOL IMAGING, vol. 43, 2016, pages 1601 - 10
ODEWOLE OATADE FINIEH PT ET AL.: "Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT", EUR J NUCL MED MOL IMAGING, vol. 43, 2016, pages 1773 - 83, XP036020275, DOI: 10.1007/s00259-016-3383-8
PERERA MPAPA NCHRISTIDIS D ET AL., EUR UROL, vol. 70, 2016, pages 926 - 37
PERNTHALER ET AL.: "A Prospective Head-to-Head Comparison of F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT", CLIN NUCL MED, vol. 44, no. 10, 2019, pages e566 - e73
PRASAD VSTEFFEN IGDIEDERICHS G ET AL., MOL IMAGING BIOL, vol. 18, 2016, pages 428 - 36
ROACH ET AL., INT J RADIAT ONCOL BIOL PHYS, vol. 65, no. 4, 2006, pages 965 - 74
SCHER ET AL.: "Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3", J CLIN ONCOL, vol. 34, no. 12, 2016, pages 1402 - 18
SCHWARZENBOCK SSOUVATZOGLOU MKRAUSE BJ: "Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer", THERANOSTICS, vol. 2, no. 3, 2012, pages 318 - 30
SIEGEL RLMILLER KDJEMAL A: "Cancer Statistics", CA CANCER J CLIN, vol. 67, no. 1, 2017, pages 7 - 30
SIEGEL RLMILLER KDJEMAL A: "Cancer Statistics", CA CANCER J CLIN, vol. 68, no. 1, 2018, pages 7 - 30
SIEGEL RLMILLER KDJEMAL A: "Cancer statistics", CA CANCER J CLIN, vol. 69, no. 1, 2019, pages 7 - 34
SMITH RAANDREWS KBROOKS D ET AL.: "Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening", CA CANCER J CLIN, vol. 66, no. 2, 2016, pages 95 - 114
VAN POPPEL ET AL., EUR J CANCER, vol. 42, 2006, pages 1062 - 7
VON EYBEN FEPICCHIO MVON EYBEN R ET AL., EUR UROL FOCUS, vol. 4, 2018, pages 686 - 93
YAXLEY JWDAGHER JDELAHUNT B ET AL., WORLD J UROL, vol. 36, 2018, pages 15 - 20
YAXLEY JWRAVEENTHIRAN SNOUHAUD FX ET AL., BJU INT, vol. 124, 2019, pages 401 - 7
YAXLEY JWRAVEENTHIRAN SNOUHAUD FX ET AL., J UROL, vol. 201, 2019, pages 815 - 20

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024216101A1 (en) * 2023-04-12 2024-10-17 Cornell University Radiotherapeutic conjugates for treating cancer
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Also Published As

Publication number Publication date
TW202304531A (zh) 2023-02-01
CN117120100A (zh) 2023-11-24
JP2024514293A (ja) 2024-04-01
IL307381A (en) 2023-11-01
KR20230165761A (ko) 2023-12-05
CA3215723A1 (en) 2022-10-06
EP4313175A1 (en) 2024-02-07
US20240181092A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
EP4313175A1 (en) Diagnostic methods of prostate cancer
Rauscher et al. Intrapatient comparison of 111In-PSMA I&T SPECT/CT and hybrid 68Ga-HBED-CC PSMA PET in patients with early recurrent prostate cancer
US20250025584A1 (en) Radiopharmaceutical treatment methods and use
La et al. Progress of coordination and utilization of zirconium-89 for positron emission tomography (PET) studies
Ilem-Ozdemir et al. Nuclear medicine and radiopharmaceuticals for molecular diagnosis
Ha et al. Dosimetric analysis of a phase I study of PSMA-targeting radiopharmaceutical therapy with [177Lu] ludotadipep in patients with metastatic castration-resistant prostate cancer
Bayat et al. Preparation and validation of [67Ga] Ga-phytate kit and Monte Carlo dosimetry: An effort toward developing an impressive lymphoscintigraphy tracer
KR20250044688A (ko) 표적화된 분자 영상화를 위한 구리의 방사성 제약 조성물
US20250269073A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
RU2702294C1 (ru) Способ радионуклидной диагностики операбельного рака молочной железы с гиперэкспрессией Her2/neu
Torres et al. State of the art and future perspectives of new radinuclides in Nuclear Medicine: Part III
Britton et al. Radiolabelled monoclonal antibodies in oncology I. Technical aspects
Ruangma et al. PSMA for PET imaging of prostate cancer
AU2018381046B2 (en) Radiolabeled progastrin in cancer diagnosis
Rudd Looking backward to move forward: A chemist’s perspective on the future of radiopharmaceuticals
US20240042067A1 (en) [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof
US20250032651A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
Lucignani Non-standard PET radionuclides: time to get ready for new clinical PET strategies
CA3085067C (en) Radiolabeled progastrin in cancer diagnosis
Bailey Advancing targeting radiopharmaceuticals for theranostic applications
PART growth factor (anti-VEGF), antiepidermal growth
Lam Translation and Development of Molecular Imaging Probes for Detecting Response of Breast Cancer to Trastuzumab
US20160193372A1 (en) Methods of identifying surrogate imaging agents for alpha emitter radiopharmaceuticals and their use in treatment of disease
Pascoe et al. Clinical Applications of Nuclear Medicine
Minamimoto et al. Positron emission tomography for future drug development

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22720606

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 307381

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 3215723

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023560269

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2022720606

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022720606

Country of ref document: EP

Effective date: 20231102

NENP Non-entry into the national phase

Ref country code: DE